===
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE'S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS
2024-07-01 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE'S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS

Vancouver, BC, Canada, June 28th, 2024 - Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB:
DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery
technologies, is please to announce that Defence's Accum-002TM ("AccuTOX®") has different mode of actions: AccuTOX® is
working as a tumor killing molecule and as an immune booster. AccuTOX® mode of action synergizes with the activity of
Immune Checkpoint Inhibitors ("ICI") and the immune system itself.
Immune Checkpoint Inhibitors produces promising therapeutic effects in treatments of solid tumors. However, their
overall response rate is still very low for a few patients suffering of solid tumors. For example, melanoma patient is
one population group having the best response with only 20% of patients having a complete or partial response to ICI
treatment. To explain the intrinsic resistant of those majority of patients to the ICI treatment, the scientific
community discovered that those tumors have a cold tumor environment which block the patient immune system to recognize
and attack the cancer cells. This cold environment is translated in part by a low level of immune infiltrating cell
inside the tumor and by decreasing the potential of the immune system to recognize tumor as a non healthy tissue and to
promote the attack and destruction of tumor cells.

The scientific and medical community is seeking solutions to this intrinsic resistance by transforming this cold tumor
into hot tumor by using combination treatments with ICI. This transformation into hot tumor will increase tumor
vulnerability to ICI treatment and to the immune system attacks.

Defence Therapeutics team have discovered that the mode of action of AccuTOX^® exploits this tumor vulnerability by
inducing immune system recruitment and increasing the tumor recognition by the immune system, which synergized with ICI
mode of actions. Surprisingly and compared to competitors, AccuTOX^® induces the recruitment and/or the activation of
different immune cells and transforms the cold tumor into very hot tumor which is easily recognized and attacked by the
immune cells. These immune cells are responsible of tumor regression in context of ICI and other immunotherapy
treatments. In other words, AccuTOX^® acts as an intelligent spotlight having specialized lens and biometric
recognition software (facial and fingerprint recognition) for the immune system to recognize, focus, track and attack
cancer tumors inside the body. AccuTOX^® has shown that it induces the death of cancer cells on its own mode of action
and, more importantly, AccuTOX^® has the potential to transform a cold tumor into a hot tumor which the immune system
will recognize, attack, and destroy.

AcccuTOX^® has the potential to treat more efficiently the patient who already has a positive response to ICI treatment
and, in fact, AccuTOX® can increase the patient population eligible to ICI treatment which shall increase the market of
each existing ICI. The Company believes that AccuTOX^® is a strong candidate to enhance and boost the therapeutic value
of the ICI and is open to potential partnerships and collaborations in that regard.

Defence's scientific team has shown in many in vivo preclinical studies that AccuTOX^® significantly increases the
efficacy of several ICI (anti-PD1, anti-CD47, anti-LAG3 and anti-CTLA4) when combined with AccuTOX^®, by at least a
factor of 10 folds, to treat different cancer indications. The PD1/PDL1 (which is the ICI used in most of Defence's
AccuTOX^®in vivo preclinical studies) market is projected to grow from USD 36.4 Billion in 2023 to USD 139.7 Billion by
2032, exhibiting a CAGR of 18.3% during the forecast period of 2023-2032.
https://www.marketresearchfuture.com/reports/pd-l1-inhibitors-market-19205

According to Allied Market Research, the global immune checkpoint inhibitors market was valued at USD USD40.1 billion in
2022, and is projected to reach USD USD189.4 billion by 2032, growing at a CAGR of 16.8% from 2023 to 2032. The primary
driver fueling the immune checkpoint inhibitors market is the rising global prevalence of cancer.
https://www.alliedmarketresearch.com/immune-check-point-inhibitors-market

About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next
generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the
ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs inside target cells and favoring their
processing and activities. As a result, increased efficacy and potency can be reached against catastrophic illness such
as cancer and infectious diseases.

For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this
release, other than statements of historical facts, that address events or developments that the Company expects to
occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends",
"estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may",
"could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include regulatory actions, market prices, and continued
availability of capital and financing, and general economic, market or business conditions. Investors are cautioned
that any such statements are not guarantees of future performance and actual results or developments may differ
materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of the Company's management on the date the statements are made. Except as required by
applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the
event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility
for the adequacy or accuracy of this release.


2024-07-01 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Defence Therapeutics Inc. 

1680 - 200 Burrard St
V6C3L6 Vancouver
Canada

E-mail:       info@defencetherapeutics.com 
Internet:     https://defencetherapeutics.com 
ISIN:         CA24463V1013 
WKN:          A3CN14 
Listed:       Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto 
EQS News ID:  1936259 

End of News EQS News Service
===
1936259 2024-07-01 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1936259&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

END) Dow Jones Newswires

July 01, 2024 02:00 ET (06:00 GMT)